These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21577272)

  • 1. Pharmacological management of atrial fibrillation: one, none, one hundred thousand.
    Lucà F; La Meir M; Rao CM; Parise O; Vasquez L; Carella R; Lorusso R; Daniela B; Maessen J; Gensini GF; Gelsomino S
    Cardiol Res Pract; 2011 Apr; 2011():874802. PubMed ID: 21577272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
    Li D; Sun H; Levesque P
    Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Present concepts in management of atrial fibrillation: From drug therapy to ablation.
    Forleo GB; Santini L; Romeo F
    World J Cardiol; 2009 Dec; 1(1):11-22. PubMed ID: 21160571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic management of atrial fibrillation: current therapeutic strategies.
    Lévy S
    Am Heart J; 2001 Feb; 141(2 Suppl):S15-21. PubMed ID: 11174354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
    Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF).
    Kirchhof P; Ammentorp B; Darius H; De Caterina R; Le Heuzey JY; Schilling RJ; Schmitt J; Zamorano JL
    Europace; 2014 Jan; 16(1):6-14. PubMed ID: 24084680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.
    Nattel S; Khairy P; Roy D; Thibault B; Guerra P; Talajic M; Dubuc M
    Drugs; 2002; 62(16):2377-97. PubMed ID: 12396229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
    Singh BN; Mody FV; Lopez B; Sarma JS
    Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When, how, and why should sinus rhythm be restored in patients with persistent atrial fibrillation?
    Stephenson K; Tschabrunn CM; Vasu S; Rashba EJ
    Curr Treat Options Cardiovasc Med; 2007 Oct; 9(5):372-8. PubMed ID: 17897566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate versus rhythm control in atrial fibrillation.
    Wijffels MC; Crijns HJ
    Cardiol Clin; 2004 Feb; 22(1):63-9. PubMed ID: 14994848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy for termination of atrial fibrillation and maintenance of sinus rhythm.
    Talajic M; Roy D
    Can J Cardiol; 2005 Sep; 21 Suppl B():19B-25B. PubMed ID: 16239983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial.
    Wong CK; White HD; Wilcox RG; Criger DA; Califf RM; Topol EJ; Ohman EM
    Card Electrophysiol Rev; 2003 Sep; 7(3):201-7. PubMed ID: 14739713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.
    Derejko P; Polańska M; Chojnowska L; Michałowska I; Wójcik A; Piotrowicz E; Lech A; Kłopotowski M; Baranowski R; Przybylski A; Bilińska M; Sierpiński R; Walczak F; Szumowski L
    Kardiol Pol; 2013; 71(1):17-24. PubMed ID: 23348529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of symptomatic atrial fibrillation.
    Haghi D; Schumacher B
    Am J Cardiovasc Drugs; 2001; 1(2):127-39. PubMed ID: 14728042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Drug Treatment Strategies for Atrial Fibrillation and TASK-1 Inhibition as an Emerging Novel Therapy Option.
    Kraft M; Büscher A; Wiedmann F; L'hoste Y; Haefeli WE; Frey N; Katus HA; Schmidt C
    Front Pharmacol; 2021; 12():638445. PubMed ID: 33897427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.